Table 1 Baseline demographics of all patients and of patients with slight progression
Patients | Nall = 103 | NSP = 48 | ||
|---|---|---|---|---|
Mean age, years ± SE | 62.27 ± 0.9 | 61.76 ± 1.62 | ||
Age range, years | 32–80 | |||
MSKCC score, mean ± SE | 1.7 ± 0.05 | 1.6 ± 0.1 | ||
Gender | ||||
Male | 80 (77.7%) | 39 | 81.3% | |
Female | 23 | 23 (22.3%) | 9 | 18.7% |
Number of patients after nephrectomy | 87 | 84.5% | 42 | 87.5% |
Comorbidities | ||||
Hypertension | 32 | 31.1% | 9 | 18.8% |
Other cardiovascular disorders | 12 | 11.6% | 5 | 10.4% |
Diabetes | 11 | 10.7% | 4 | 8.3% |
Secondary tumors | 9 | 8.7% | 1 | 2% |
Hyperthyroidism | 5 | 4.9% | 0 | 0% |
Hematological disease | 3 | 2.9% | 0 | 0% |
Psoriasis | 2 | 1.9% | 0 | 0% |
Metastases | ||||
Mean number of metastatic sites (range) | 2.32 ± 0.11 (1–5) | 1.79 ± 0.1 (1–3) | ||
Location of metastases | ||||
Lungs | 84 | 81.6% | 39 | 81.2% |
Bone | 47 | 45.6% | 16 | 33.3% |
Distant lymph node | 36 | 34.9% | 20 | 41.7% |
Liver | 19 | 18.4% | 7 | 14.6% |
Brain | 11 | 10.7% | 0 | 0% |
Suprarenal gland | 9 | 8.7% | 4 | 8.3% |
Other (peritoneum, pleura, pancreas, local relapse, contralateral kidney, or thyroid gland) | – | ‹8% | – | ‹4% |
Patients with synchronous metastases | 94 | 91.2% | 45 | 93.8% |
Histopathological types | n | % | ||
Purely clear cell renal cell type (ccRCC) | 91 | 88.3% | 46 | 95.8% |
ccRCC with sarcomatoid morphology | 7 | 6.8% | 1 | 2% |
ccRCC with papillary−/chromophobe−/ both | 3 / 2 / 1 | 2.9 / 1.9 / 1.0% | 1/0/0 | 2/0/0% |